Medicare prescription drug benefit realities

MedGenMed Medscape General Medicine

Volumn 5, Issue 4, 2003, Pages

  Cundiff, David K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE BESYLATE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CISPLATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXAZOSIN; ENALAPRIL MALEATE; GEFITINIB; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHYLDOPA; MEVINOLIN; PLACEBO; THIAZIDE DIURETIC AGENT;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST CONTROL; COST OF ILLNESS; DIET THERAPY; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG FATALITY; HEALTH CARE COST; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; LUNG NON SMALL CELL CANCER; MEDICARE; MORTALITY; PRESCRIPTION; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; SYSTOLIC HYPERTENSION; TERMINAL DISEASE;

EID: 25144439883     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Medicare Prescription Drug Spending Chartpack. The Kaiser Family Foundation. June 26, 2003. Available at: http://www.allhealth.org/recent/audio_06-26-03/KaiserChartPack.pdf. Accessed September 4, 2003.
2. National Health Expenditures and Selected Economic Indicators, Levels and Average Annual Percent Change: Selected Calendar Years 1980-2011. Baltimore, Md: Centers for Medicare & Medicaid Services, Office of the Actuary; 2002. Available at: http://cms.hhs.gov/statistics/nhe/projections-2001/t1.asp. Accessed December 1, 2003.
3. How Good Is the Quality of Health Care in America?: Rand Corporation. Available at: http://www.rand.org/news/press.03/06.25fact.html. Accessed December 1, 2003
4. Gold M, Achman L. Average Costs for Medicare+Choice Enrollees Doubled in Four Years. New York, NY: Commonwealth Fund; 2003. Available at: http://www.cmwf.org/programs/medfutur/gold_averageoopcosts_ib_667.pdf
5. Eisenberg JM. Evidence-based medicine - a paradigm shift is underway in health care. National Institute for Health Care Management; 2001. Available at: http://www.nihcm.org/ExpertV1.pdf. Accessed December 1, 2003.
6. Temodal (Temozolomide) Schering Corporation. Indicated for the Treatment of Adult Patients With Malignant Glioma (Glioblastoma Multiforme and Anaplastic Astrocytoma) at First Relapse. Oncologic Drugs Advisory Committee. 60th edition. Gaithersburg, Md: Dept. of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research; 1999:154.
7. Policy Statement: Coverage of Unlabeled Drug Indications. Alexandria, Va: American Society of Clinical Oncology; 1993. Available at: http://www.asco.org/ac/1,1003,_12-002217-00_18-0010345- 00_19-00-00_20-001,00.asp. Accessed December 2, 2003.
8. US Food and Drug Administration. FDA Oncology Tools Approval Summary for Locally Advanced or Metastatic Non-small Cell Lung Cancer. Rockville, Md: US Food and Drug Administration, Center for Drug Evaluation and Research; 2003.
9. Miller AB, To T, Baines CJ, Wall C. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years. Ann Intern Med. 2002;137:305-312.
10. FDA Approves New Type of Drug for Lung Cancer. Rockville, Md: Food and Drug Administration; 2003. Available at: http://www.fda.gov/bbs/topics/NEWS/2003/NEW00901.html. Accessed December 1, 2003.
11. Gefitinib (Iressa). drugstore.com (online drug store). Available at: http://www.drugstore.com/pharmacy/prices/drugprice.asp?ndc= 00310048230&trx=1Z5006. Accessed December 2, 2003.
12. Cancer Facts and Figures 2003. American Cancer Society. Available at: http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf. Accessed Dec. 2, 2003.
13. Riley G, Lubitz J, Prihoda R, Rabey E. The use and costs of Medicare services by cause of death. Inquiry. 1987;24:233-244.
14. Medicare Program Information. Vol. 2002: Centers for Medicare and Medicaid Services. Available at: http://cms.hhs.gov/charts/series/sec3%2Db5.pdf. Accessed December 1, 2003.
15. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending. Part 1: the content, quality, and accessibility of care. Ann Intern Med. 2003;138:273-287.
16. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA. 2001;285:2486-2497.
17. Listing of Drug Product Information by Retail Sales: myOrangeBook.com. Available at: http://www.myorangebook.com/subs/Sales/2001.php. Access requires subscription.
18. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
19. FDA Approves ZETIA(TM) (ezetimibe) for Cholesterol Reduction: Merck/Schering-Plough Pharmaceuticals. Available at: http://www.zetia.com/ezetimibe/zetia/hcp/press_release/index.jsp. Accessed December 1, 2003.
20. Jenkins DJA, Kendall CWC, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA. 2003;290:502-510.
21. American Heart Association. Heart Disease and Stroke Statistics - 2003 Update. Dallas, Tex: American Heart Association; 2002.
22. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. JAMA. 2003;289:2560-2572.
23. Leren P, Helgeland A. Coronary heart disease and treatment of hypertension. Some Oslo Study data. Am J Med. 1986;80:3-6.
24. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1979;242:2562-2571.
25. Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial. Plan and preliminary results of a two-year feasibility trial for a multicenter intervention study to evaluate the benefits versus the disadvantages of treating mild hypertension. Prepared for the Veterans Administration-National Heart, Lung, and Blood Institute Study Group for Evaluating Treatment in Mild Hypertension. Ann N Y Acad Sci. 1978;304:267-292.
26. Neaton JD, Grimm RHJ, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA. 1993;270:713-724.
27. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. JAMA. 2002;288:2981-2997.
28. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 1997;336:1117-1124.
29. Harris G. Debate Resumes on the Safety of Depression's Wonder Drugs. New York Times. August 7, 2003. Available at: http://www.nytimes.com/2003/08/07/health/07DEPR.html?pagewanted= all&position=. Accessed December 1, 2003.
30. FDA Issues Public Health Advisory Entitled: Reports Of Suicidality in Pediatric Patients Being Treated With Antidepressant Medications for Major Depressive Disorder (MDD). Rockville, Md: US Food and Drug Administration, Department of Health and Human Services; 2003. Available at: http://www.fda.gov/bbs/topics/ANSWERS/2003/ANS01256.html. Accessed December 3, 2003.
31. DO NOT USE! Teriparatide (FORTEO) - A New Drug For Osteoporosis: Public Citizen Health Research Project; 2003.
32. Cundiff DK. Anticoagulants for non valvular atrial fibrillation (NVAF) - drug review. Medscape General Medicine; 2003. Available at: http://www.medscape.com/viewarticle/448817. Accessed December 1, 2003.
33. Cundiff DK. Insufficient evidence supporting low-intensity warfarin for venous thromboembolism (VTE) prophylaxis - Commentary. Medscape General Medicine; 2003. Available at: http://www.medscape.com/viewarticle/457570. Accessed December 1, 2003.
34. Taylor FC, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ. 2001;322:321-326.
35. Cundiff DK. Review article - thrombolysis for acute myocardial infarction: drug review. Medscape General Medicine; 2002. Available at: http://www.medscape.com/viewarticle/414942. Accessed December 1, 2003.
36. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess. 2001;5:1-81.
37. Wolfe SM, Sasich LD, Barbehenn E. Petition to FDA to ban the diet drug sibutramine (MERIDIA) (HRG Publication #1613). Public Citizen Health Research Group; 2002.
38. Do not use celecoxib (CELEBREX) and rofecoxib (VIOXX) for arthritis - the misnamed and overpriced "super aspirins." Public Citizen Health Research Project; 2001.
39. COX-2 inhibitors update: Do journal publications tell the full story? Therapeutics Letter. November/December 2001 & January 2002. Available at: http://www.ti.ubc.ca/pages/letter43.htm. Accessed December 3, 2003.
40. Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending. Part 2: health outcomes and satisfaction with care. Ann Intern Med. 2003;138:288-298.
41. Proposal of the Physicians' Working Group for Single-Payer National Health Insurance - The Physicians' Working Group for Single-Payer National Health Insurance. JAMA. 2003;290:798-805.